Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.56 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.56 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.53 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456458 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL19557778 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL1456455 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL12377250 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL20143550 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL1456463 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL277126 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| Hexadecanoic Acid Isopropylamide SCHEMBL1457147 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL12459875 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL5005939 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137852-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20230302091-A1 | Combination Therapy with Controlled-Release CNP Agonists | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2023-09-28 | — | — | US | disclosed |
| US-20230158169-A1 | LINKERS FOR IMPROVING THE STABILITY OF BIOCONJUGATES AND THE SELECTIVITY OF PAYLOAD RELEASE | AUDAX PRIVATE DEBT LLC, AS AGENT | 2023-05-25 | — | — | US | disclosed |
| US-20230066830-A1 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER STEM CELLS | UNIV VIRGINIA COMMONWEALTH (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220218829-A1 | NUCLEIC ACID CONJUGATES AND USES THEREOF | TRANSLATE BIO MA, INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-20210052706-A1 | COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS | TRANSLATE BIO MA, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| WO-2018013525-A1 | NUCLEIC ACID CONJUGATES AND USES THEREOF | TRANSLATE BIO MA, INC. (US) | 2018-01-18 | — | — | WO | disclosed |
| WO-2011066414-A1 | ARACHIDONIC ACID ANALOGS AND METHODS FOR ANALGESIC TREATMENT USING SAME | CYTOMETIX, INC. (US) | 2011-06-03 | — | — | WO | disclosed |
| WO-2009086835-A1 | NOVEL CYANOGUANIDINES | TOPOTARGET A/S (DK) | 2009-07-16 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| US-5224987-A | Aqueous carriers with colors and tertiary amide penetrants | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052706-A1 | COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS | NSUN3, RNGTT, CSGALNACT1 | FAAH 4037/4885MEN1 2571/4885KMT2A 2296/4885 |
| US-20230158169-A1 | LINKERS FOR IMPROVING THE STABILITY OF BIOCONJUGATES AND THE SELECTIVITY OF PAYLOAD RELEASE | CTSA, CTSS, CTSV | FAAH 645/4885MEN1 3517/4885KMT2A 3207/4885 |
| US-20230066830-A1 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER STEM CELLS | SDCBP, BAX, MCL1 | FAAH 3941/4885MEN1 4230/4885KMT2A 4100/4885 |
| US-20220218829-A1 | NUCLEIC ACID CONJUGATES AND USES THEREOF | FOLR1, SLC19A1, FOLR2 | FAAH 4087/4885MEN1 1700/4885KMT2A 2105/4885 |
| US-20230302091-A1 | Combination Therapy with Controlled-Release CNP Agonists | CNP, NPR1, NGF | FAAH 582/4885MEN1 1072/4885KMT2A 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.